Jiangxi Healthcare Security Administration Launches New VBP Tender

The Jiangxi Healthcare Security Administration (JHSA) has released a notice of a new volume-based procurement (VBP) tender. Jiangxi’s JHSA will lead a 16-region alliance covering Inner Mongolia, Jilin, Heilongjiang, Zhejiang, Henan, Hunan, Guangxi, Hainan, Chongqing, Guizhou, Shaanxi, Qinghai, Ningxia, Xinjiang, and the Xinjiang Production and Construction Corps. This initiative aims to streamline the procurement process and ensure the availability of essential medical products.

Tender Details
The VBP will involve products that have failed to pass the generic quality consistency evaluation (GQCE), including 13 varieties such as papaverine, tropisetron, gastrodin, and vitamin D. The application and evaluation process will be divided into an economic and technical bid and a commercial bid. The economic and technical bid will be scored according to a hundred-point system, with scores calculated based on bidding application materials and legal certification from relevant functional departments. The highest-scoring products in each bidding group, categorized by drug name and combined medical insurance dosage form, will be selected for evaluation. The commercial bid, with a full score of 100 points, will include 50 points for the quotation decrease and 50 points for the absolute value of the quotation.

Procurement Cycle and Agreement
Purchase volumes for exclusive winners in the first year will be 50% of the purchase volume base. If two companies win the bid, the lowest price winner will receive 50% of the purchase volume base, and the highest-scoring winner will receive 25%. The procurement cycle is set for two years, with agreements signed annually.

Future Implications
This new VBP tender led by the Jiangxi Healthcare Security Administration marks a significant step in optimizing the procurement of medical products across multiple regions. By focusing on products that have not passed the GQCE, the initiative aims to enhance the quality and availability of essential medications, ultimately benefiting patients and healthcare providers.-Fineline Info & Tech

Insight, China's Pharmaceutical Industry